Dr Reddy's Laboratories (FRA:RDDA) Short-Term Debt : €141 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Dr Reddy's Laboratories Short-Term Debt?

Dr Reddy's Laboratories's Short-Term Debt for the quarter that ended in Mar. 2024 was €141 Mil.

Dr Reddy's Laboratories's quarterly Short-Term Debt increased from Sep. 2023 (€66 Mil) to Dec. 2023 (€136 Mil) and increased from Dec. 2023 (€136 Mil) to Mar. 2024 (€141 Mil).

Dr Reddy's Laboratories's annual Short-Term Debt declined from Mar. 2022 (€323 Mil) to Mar. 2023 (€127 Mil) but then increased from Mar. 2023 (€127 Mil) to Mar. 2024 (€141 Mil).

Dr Reddy's Laboratories Short-Term Debt Historical Data

The historical data trend for Dr Reddy's Laboratories's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Short-Term Debt Chart

Dr Reddy's Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Short-Term Debt

Get a 7-Day Free Trial

246.62

266.99

322.75

127.04

140.99

Dr Reddy's Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															127.04	72.61	66.00	135.95	140.99

Dr Reddy's Laboratories Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Dr Reddy's Laboratories Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (FRA:RDDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (FRA:RDDA) » Definitions » Short-Term Debt

Traded in Other Exchanges

RDY:USA DRREDDY:India 500124:India RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (FRA:RDDA) Headlines

No Headlines